| Trial ID: | L2635 |
| Source ID: | NCT03331289
|
| Associated Drug: |
Placebo
|
| Title: |
Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT03331289/results
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Placebo|DRUG: Exenatide|DRUG: Dapagliflozin|DRUG: Exenatide and Dapagliflozin
|
| Outcome Measures: |
Primary: Change in EGP From Baseline to Post-oral Glucose Load., The difference in rate of EGP during the last hour of the study (from 240-300 minutes) between drug-treatment and placebo treatment studies represents the effect of drug treatment on EGP, which will be compared among the 3 acute drug treatments (exenatide; dapagliflozin; exenatide plus dapagliflozin this data includes change in EGP above baseline following dapagliflozin alone vs dapagliflozin/exenatide) with ANOVA., From baseline [-35 to 0min] to the last hour post-glucose load [240-300 minutes] |
|
| Sponsor/Collaborators: |
Sponsor: The University of Texas Health Science Center at San Antonio | Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
107
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2018-02-28
|
| Completion Date: |
2022-11-04
|
| Results First Posted: |
2023-07-24
|
| Last Update Posted: |
2023-07-24
|
| Locations: |
University Health System Texas Diabetic Institute, San Antonio, Texas, 78207, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT03331289
|
